Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.

Saved in:
Bibliographic Details
Title: Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
Authors: Croden J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bouligny IM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alvarado-Valero Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva MY; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. CDiNardo@mdanderson.org.
Source: Leukemia [Leukemia] 2025 Oct; Vol. 39 (10), pp. 2538-2541. Date of Electronic Publication: 2025 Aug 14.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-025-02733-0